Cover Image

Evaluating the Treatment with Favipiravir in Patients Infected by COVID-19: A Systematic Review and Meta-analysis

Background and aim: Considering the results of studies and the potential of using favipiravir treatment of COVID-19, reviewing the results of clinical trial studies and summarizing the results are of great importance. It may be possible to use favipiravir extensively in the future. Therefore, the pu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fu Fu Wei (Author), Azadeh Moradkhani (Author), Hedieh Hemmati Hezaveh (Author), Seyedeh Atefeh Miraboutalebi (Author), Lida Salehi (Author)
Format:	Book
Published:	International Journal of Scientific Research in Dental and Medical Sciences (IJSRDMS), 2020-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review
by: Pradeep Balasubramanian, et al.
Published: (2022)

Population pharmacokinetics of favipiravir in patients with COVID‐19
by: Kei Irie, et al.
Published: (2021)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
by: Yusuke Asai, et al.
Published: (2023)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
by: Rahmet Guner, et al.
Published: (2021)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
by: Kei Irie, et al.
Published: (2020)

Current and future use of favipiravir in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020)

Evaluation of the Survival Rate and Clinical Outcome of Nanodrug Administration for the Treatment of Lung Cancer: A Systematic Review and Meta-analysis
by: Marzieh Khalili, et al.
Published: (2022)

Evaluation of Nephrotoxic Properties of Favipiravir Using the RPTEC cell model
by: V. A. Evteev, et al.
Published: (2023)

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.
by: Pierangelo Chinello, et al.
Published: (2017)

Favipiravir and hyperuricemia in patients with COVID-19-suggestions for future studies
by: Chia Siang Kow, et al.
Published: (2023)

EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
by: L. A. Balykova, et al.
Published: (2022)

A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
by: Victoria Pilkington, et al.
Published: (2020)

Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study
by: Zainab Almoosa, et al.
Published: (2021)

Pharmacokinetic Interaction of Favipiravir with Citalopram and Pioglitazone
by: Zeliha Keskin Alkaç, et al.
Published: (2022)

Favipiravir-Tautomeric and Complexation Properties in Solution
by: Vera Deneva, et al.
Published: (2022)

Pharmacogenomic Studies of Antiviral Drug Favipiravir
by: Victoria V. Shumyantseva, et al.
Published: (2024)

Novel Polymorph of Favipiravir-An Antiviral Medication
by: Alexander S. Goloveshkin, et al.
Published: (2021)

Prevalence of Malignancy and Chronic Obstructive Pulmonary Disease among Patients with COVID-19: A Systematic Review and Meta-analysis
by: Somaye Jamali, et al.
Published: (2020)

Eccrine chromhidrosis in severe acute respiratory syndromecoronavirus- 2 virus infection treated with favipiravir
by: Müge Göre Karaali, et al.
Published: (2022)

Case report: Favipiravir-induced bluish corneal discoloration in infant with COVID-19
by: Paveewan Jiravisitkul, et al.
Published: (2023)

The administration of interferon-beta1b and favipiravir in patients with COVID-19 pneumonia
by: Mehrdad Hasibi, et al.
Published: (2021)

Does Favipiravir Reduce Mortality in Patients with COVID-19 ARDS and Severe Pneumonia?
by: Khin Zar Li Aung, et al.
Published: (2021)

Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir
by: Qiongqiong Fang, et al.
Published: (2020)

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
by: Thi Huyen Tram Nguyen, et al.
Published: (2017)

Systematic review and meta-analysis of Tuberculosis and COVID-19 Co-infection: Prevalence, fatality, and treatment considerations.
by: Quan Wang, et al.
Published: (2024)

Systematic review and meta-analysis of Tuberculosis and COVID-19 Co-infection: Prevalence, fatality, and treatment considerations
by: Quan Wang, et al.
Published: (2024)

Evaluation of [<sup>18</sup>F]Favipiravir in Rodents and Nonhuman Primates (NHP) with Positron Emission Tomography
by: Jian Rong, et al.
Published: (2023)

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers.
by: Denis Malvy, et al.
Published: (2020)

When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study
by: Khalid Al Sulaiman, et al.
Published: (2023)

Discovery of novel favipiravir derivatives with improved pharmacokinetic properties as anti-SFTSV agents
by: Xiaomeng He, et al.
Published: (2024)

A case of disseminated erythematous drug eruption caused by favipiravir in a patient with COVID‐19
by: Aki Honda, et al.
Published: (2023)

Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
by: Bandar Alosaimi, et al.
Published: (2022)

Follow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs
by: Hüsna Güder, et al.
Published: (2023)

STUDY OF CLINICAL AND PATHOGENETIC EFFECTS OF ANTI-VIRAL DRUG BASED ON FAVIPIRAVIR IN COMORBID PATIENTS WITH COVID-19 AT THE OUTPATIENT STAGE OF TREATMENT
by: L. A. Balykova, et al.
Published: (2021)

Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand
by: Pinyo Rattanaumpawan, et al.
Published: (2022)

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever.
by: Brian B Gowen, et al.
Published: (2013)

Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study
by: Rand A. Alattar, et al.
Published: (2022)

Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever.
by: Lisa Oestereich, et al.
Published: (2014)

The Development and the Validation of a Novel Dissolution Method of Favipiravir Film-Coated Tablets
by: Özge Göktuğ, et al.
Published: (2021)

Personal protective equipment-associated headaches in health care workers during COVID-19: A systematic review and meta-analysis
by: Ali Sahebi, et al.
Published: (2022)